Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and Stanford University School of Medicine. It aimed...
-
The Extraordinary General Meeting in Hofseth BioCare ASA was held at the premises of the Company in Ålesund, Norway today Tuesday 30 August 2022. All matters were approved according to the...
-
Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Letter for ProGo® Bioactive Peptides. Summary Highlights...
-
HBC had gross operating revenues of NOK 25.8m (31.0m) in the second quarter. For the first half of 2022 HBC had revenues of NOK 56.6m (47.9m). Cost of sales (CoGS) amounted to NOK 17.7m (21.6m) in the...
-
An Extraordinary General Meeting of Hofseth BioCare ASA will be held at the company's premises at Kipervikgata 13, 6003 Ålesund, on 30 August 2022 at 13:00 CET. Please find the notice to the General...
-
In the annual general meeting of Hofseth BioCare ASA (the "Company") held on 29 April 2022, the general meeting resolved to carry out a private placement towards Brilliant Invest 2 AG as part of an...
-
Following years of strong growth in Hofseth International AS ("Hofseth International") and the expected further positive development in Hofseth BioCare ASA's ("HBC") revenues and sales activities, it...
-
Reference is made to the stock exchange notice from Hofseth BioCare ASA ("HBC" or the "Company") published on 3 July 2022 regarding the completion of a private placement raising gross proceeds of...
-
Ålesund, Norway – 11 July 2022. Reference is made to the stock exchange announcement on 3 July 2022 regarding the completion of a private placement (the "Private Placement") in Hofseth BioCare ASA. ...
-
Reference is made to the stock exchange announcement by Hofseth BioCare ASA (the "Company") on 3 July 2022 regarding completion of a private placement of new shares (the "Private Placement"). In the...